Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

What Was Tested

This randomized controlled trial looks at C-Peptide.

Herein, the researchers report 2-year area under the curve (AUC) C-peptide and HbA1c, prespecified secondary end points, and potential immunologic correlates.

Who Took Part

The abstract describes 2 subjects taking part.

By PubMed's age tags, the people studied were children, teenagers, young adults and adults, both men and women.

Subjects (N = 89) were randomized to 1) ATG and pegylated granulocyte colony-stimulating factor (GCSF), 2) ATG alone, or 3) placebo.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this C-Peptide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on C-Peptide, so expectations could not easily colour the readings.

Some subjects received a placebo instead of C-Peptide, giving a reference point.

What Was Measured

Herein, the researchers report 2-year area under the curve (AUC) C-peptide and HbA1c, prespecified secondary end points, and potential immunologic correlates.

The subject headings attached to it are Antilymphocyte Serum, C-Peptide, CD4-CD8 Ratio, Diabetes Mellitus, Type 1, Flow Cytometry, Glycated Hemoglobin and Granulocyte Colony-Stimulating Factor.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of C-Peptide in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2019 (Diabetes), a journal based in United States.

More context: the C-Peptide compound page, all human trials.